Another factor contributing to the low objective response rate in PD-1/PD-L1 blocking therapy is the rapid depletion of tumor-targeted CTLs inside the TME, preventing them from exerting a sustained and potent anti-tumor impact [112]. This evidence concerns the gene PDCD1 and neoplasm.